{
  "id": 20725444,
  "title": "Celltrion Extends Biosimilar Lead Across Asia",
  "url": "https://urgent.news/2026/11/19/celltrion-extends-biosimilar-lead-across-asia",
  "topic": "business",
  "section": "Business",
  "published": "2026-11-19T08:56:51.000Z",
  "source": {
    "name": "BusinessKorea",
    "slug": "businesskorea",
    "url": "https://www.businesskorea.co.kr/news/articleView.html?idxno=281725"
  },
  "original_language": "en",
  "account": "Celltrion is strengthening its position in Asia with its biosimilar product lineup, which includes autoimmune disease treatments and anticancer therapies. The company reported maintaining its leading market share in key Asian countries such as Malaysia, Singapore, and Thailand through an optimized direct sales strategy that caters to each country's bidding environment and medical institution demand. According to IQVIA's pharmaceutical market research, Celltrion's flagship autoimmune disease treatment 'Remsima' held a 95% market share in Singapore, 83% in Hong Kong, and 75% in Malaysia in the second quarter of 2026. Similarly, in the oncology sector, its breast and gastric cancer treatment 'Herzuma' (trastuzumab) ranked first in Hong Kong (67%), Thailand (59%), and Malaysia (52%). In Thailand, 'Remsima' increased its market share by 17 points, widening its lead over competing products. For blood cancer treatment, 'Truxima' (rituximab) secured a 92% market share in Singapore, 78% in Thailand, and 41% in Hong Kong. In Malaysia, the oncology treatment 'Vegzelma' (bevacizumab) climbed to first place in Q1 2026, growing its market share from 25% in Q4 2025. Celltrion attributes its success to a local direct sales strategy that ensures stable supply and swift response to medical institutions, along with collaborating with major medical institutions and participating in academic conferences to highlight product clinical strengths. The company is also launching new, high-margin products, utilizing existing flagship product networks to accelerate market share growth. Celltrion plans to introduce 'Vegzelma' in Hong Kong by November, 'Stoboclo' (denosumab) to Thailand in December, and 'Eydenzelt' (aflibercept) in Singapore and 'Omyqlo' in Thailand in February 2027. This success demonstrates how Celltrion's consolidated direct sales infrastructure, established as a first-generation biosimilar leader in Asia, acts as a \"virtuous cycle foothold,\" lowering costs for future high-margin launches and maximizing profitability.",
  "summary": "Celltrion is solidifying its dominance in the Asian region, a representative pharmerging (emerging pharmaceutical) market, driven by the overwhelming market share of its flagship product lineup for autoimmune diseases and anticancer treatments.Celltrion announced on Nov. 19 that it is maintaining th",
  "key_points": [
    "Celltrion maintains 95% market share in Singapore for autoimmune treatment Remsima.",
    "Herzuma ranks first in Hong Kong, Thailand, and Malaysia for breast and gastric cancer.",
    "Truxima secures 92% market share in Singapore for blood cancer treatment."
  ],
  "editors_take": "Celltrion’s optimized direct sales infrastructure in Asia creates a virtuous cycle that lowers costs for new high-margin launches while cementing its dominance across the autoimmune and oncology sectors.",
  "illustration": null,
  "coverage": {
    "outlets": 1,
    "also_reported_by": []
  },
  "ai_generated": true,
  "disclaimer": "Summaries, key points and the editor’s take are written by software from other outlets’ reporting and may contain errors — always check the linked original."
}